{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:09:49Z","timestamp":1790104189391,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.pathol.2019.10.007","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T08:10:05Z","timestamp":1576829405000},"page":"197-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A detailed morphological and immunohistochemical comparison of primary endometrial and tubo-ovarian high-grade serous carcinomas and their corresponding omental metastases"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1292-0301","authenticated-orcid":false,"given":"Sukeerat","family":"Ruba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5507-9065","authenticated-orcid":false,"given":"Dorota","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin J.R.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2019.10.007_bib1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/PGP.0b013e31826ddc4e","article-title":"An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas","volume":"32","author":"Zhang","year":"2013","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/PAS.0000000000000369","article-title":"Evidence for a dualistic model of high-grade serous carcinoma","volume":"39","author":"Howitt","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/PAS.0000000000000757","article-title":"Uterine serous carcinomas frequently metastasize to the fallopian tube and can mimic serous tubal intraepithelial carcinoma","volume":"41","author":"Kommoss","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib4","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/1471-0528.14543","article-title":"Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: a systematic review","volume":"124","author":"Chen","year":"2017","journal-title":"BJOG"},{"key":"10.1016\/j.pathol.2019.10.007_bib5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PGP.0000000000000270","article-title":"Adopting a uniform approach to site assignment in tubo-ovarian high-grade serous carcinoma: the time has come","volume":"35","author":"Singh","year":"2016","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PGP.0000000000000336","article-title":"The fallopian tube origin and primary site assignment in extrauterine high-grade serous carcinoma: findings of a survey of pathologists and clinicians","volume":"36","author":"McCluggage","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/modpathol.2008.108","article-title":"Immunophenotyping of serous carcinoma of the female genital tract","volume":"21","author":"Nofech-Mozes","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1309\/K84K-005F-TCB8-FV4B","article-title":"WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas","volume":"117","author":"Goldstein","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cncr.27720","article-title":"BRCA1, TP53 and CHEK2 germline mutations in uterine serous carcinoma","volume":"119","author":"Pennington","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2019.10.007_bib10","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"11","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pathol.2019.10.007_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejca.2016.11.028","article-title":"Linking uterine serous carcinoma to BRCA1\/2-associated cancer syndrome: a meta-analysis and case report","volume":"72","author":"De Jonge","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pathol.2019.10.007_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2559.2004.01787.x","article-title":"WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma","volume":"44","author":"Al-Hussaini","year":"2004","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2019.10.007_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5858\/arpa.2014-0057-RA","article-title":"The utility of immunohistochemistry in the differential diagnosis of gynecologic disorders","volume":"139","author":"Kaspar","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2019.10.007_bib14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/PGP.0000000000000291","article-title":"Immunohistochemical profiling of endometrial serous carcinoma","volume":"36","author":"Chen","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/01.pgp.0000235065.31301.3e","article-title":"Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma","volume":"26","author":"Chiesa-Vottero","year":"2007","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib16","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1097\/PAS.0b013e3181ac35f5","article-title":"Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases","volume":"33","author":"Yemelyanova","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/modpathol.2011.183","article-title":"Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma","volume":"25","author":"Soslow","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/IGC.0000000000000834","article-title":"Value of specialist pathology review in a single statewide gyneecologic cancer service","volume":"27","author":"Melon","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.pathol.2019.10.007_bib19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pathol.2019.03.002","article-title":"Evaluation of pathology review at gynaecological oncology multidisciplinary team meetings: a 5-year prospective analysis of cases with major diagnostic discordance","volume":"51","author":"Stewart","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2019.10.007_bib20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2005.04.109","article-title":"Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy","volume":"23","author":"Powell","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2019.10.007_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.pap.0000201826.46978.e5","article-title":"Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer","volume":"13","author":"Lee","year":"2006","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/PAT.0b013e328359d636","article-title":"Immunohistochemical expression and prognostic significance of oestrogen receptor-alpha, oestrogen receptor-beta, and progesterone receptor in stage 1 adult-type granulosa cell tumour of the ovary","volume":"44","author":"Hutton","year":"2012","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2019.10.007_bib23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pathol.2017.10.013","article-title":"An immunohistochemical and molecular analysis of papillary proliferation of the endometrium","volume":"50","author":"Stewart","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2019.10.007_bib24","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/modpathol.3800827","article-title":"Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary M\u00fcllerian system origin?","volume":"20","author":"Tong","year":"2007","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/PGP.0b013e318226b376","article-title":"PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia","volume":"31","author":"Allison","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib26","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/PAS.0000000000000436","article-title":"Immunohistochemical comparison of ovarian and uterine endometrioid carcinoma, endometrioid carcinoma with clear cell change, and clear cell carcinoma","volume":"39","author":"Lim","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/PGP.0b013e318182c2d2","article-title":"Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma","volume":"28","author":"Phillips","year":"2009","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.mce.2004.02.020","article-title":"Estrogen and progesterone receptors in ovarian epithelial tumors","volume":"221","author":"Lindgren","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pathol.2019.10.007_bib29","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5858\/arpa.2012-0416-RA","article-title":"HER2\/neu in endometrial cancer. A promising therapeutic target with diagnostic challenges","volume":"138","author":"Buza","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2019.10.007_bib31","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score; development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"22","author":"B\u00f6hm","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2019.10.007_bib32","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/IGC.0000000000000945","article-title":"Prognostic role of histological tumor regression in patients receiving neoadjuvant chemotherapy for high-grade serous tubo-ovarian carcinoma","volume":"27","author":"Coghlan","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.pathol.2019.10.007_bib33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ygyno.2019.04.679","article-title":"Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data","volume":"154","author":"Cohen","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2019.10.007_bib34","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"21","author":"Alsop","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2019.10.007_bib35","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/PGP.0b013e31820d20ba","article-title":"Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites","volume":"30","author":"K\u00f6bel","year":"2011","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib36","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.path.2010.12.004","article-title":"High-grade serous carcinoma involving fallopian tube, ovary and peritoneum","volume":"4","author":"Al-Agha","year":"2011","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.pathol.2019.10.007_bib37","first-page":"161","article-title":"Histologic subtypes of ovarian carcinoma: an overview","volume":"27","author":"Soslow","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/PGP.0b013e31824d7445","article-title":"Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor","volume":"31","author":"Ali","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib39","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/PAS.0b013e3182834d41","article-title":"Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma","volume":"37","author":"Takeuchi","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/PAT.0b013e328348a6e7","article-title":"Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis","volume":"43","author":"McCluggage","year":"2011","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2019.10.007_bib41","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/modpathol.2016.82","article-title":"Morphologic correlates of molecular alterations in extrauterine M\u00fcllerian carcinomas","volume":"29","author":"Ritterhouse","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib42","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/modpathol.2013.237","article-title":"Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency","volume":"27","author":"Reyes","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib43","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/PAS.0000000000000556","article-title":"Invasion patterns of metastatic extrauterine high-grade serous carcinoma with BRCA germline mutation and correlation with clinical outcomes","volume":"40","author":"Hussein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib44","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/PAP.0b013e318234aaed","article-title":"WT1 expression in the female genital tract","volume":"18","author":"B\u00e1rcena","year":"2011","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib45","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/his.13272","article-title":"A\u00a0comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy","volume":"71","author":"Casey","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2019.10.007_bib46","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/01.pas.0000168174.25664.04","article-title":"Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps","volume":"29","author":"Eusher","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib47","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.humpath.2014.05.009","article-title":"The frequency and significance of WT-1 expression in serous endometrial carcinoma","volume":"45","author":"Hedley","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pathol.2019.10.007_bib48","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.anndiagpath.2013.04.011","article-title":"Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas","volume":"17","author":"Fadare","year":"2013","journal-title":"Ann Diagn Pathol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302519304350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302519304350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:25:14Z","timestamp":1758471914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302519304350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0031302519304350"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2019.10.007","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A detailed morphological and immunohistochemical comparison of primary endometrial and tubo-ovarian high-grade serous carcinomas and their corresponding omental metastases","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2019.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}